U.S. Software Stock News

Kodiak Sciences (NasdaqGM:KOD) reported positive Phase 3 GLOW2 results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The drug showed superiority over sham treatment, supporting a potential multi indication BLA submission. The update follows earlier focus on KSI-101 and adds fresh validation for Kodiak’s ABC platform in retinal disease. Kodiak Sciences, trading at $43.68, now has clinically meaningful Phase 3 data for Zenkuda that relates directly to its lead pipeline asset. The...

Zoetis (ZTS) has opened 2026 with Q1 revenue of US$2.3b and basic EPS of US$1.42, setting the tone for how investors read the latest earnings update. The company has seen quarterly revenue move from US$2.2b in Q1 2025 to US$2.3b in Q1 2026, while basic EPS shifted from US$1.41 to US$1.42 over the same period, giving you a clear view of how the top and bottom lines are tracking year on year. Against that backdrop, the focus now is on how sustainably Zoetis is converting this revenue into...

Sensata Technologies Holding plc has reported past first-quarter 2026 results showing sales of US$934.8 million and net income of US$87.1 million, alongside new second-quarter guidance and an update on its ongoing share repurchase program. Together, the stronger quarterly earnings, forward earnings guidance, and completion of a multi-year buyback provide fresh insight into how Sensata is balancing growth investment with returning capital to shareholders. Next, we will examine how Sensata’s...

Arcus Biosciences (RCUS) has been in focus after first quarter 2026 results, which showed revenue of US$17 million and a net loss of US$128 million, alongside several pipeline and collaboration setbacks. See our latest analysis for Arcus Biosciences. The share price has been volatile around the recent Q1 2026 update and pipeline news. The 1 month share price return is 12.28% and the 90 day share price return is 17.83%, while the 1 year total shareholder return of 190.50% contrasts with a...

Artificial intelligence in healthcare sits at the crossroads of powerful data, rising care costs, and a world focused on inflation, energy shocks, and supply chain shifts. While oil, rates, and trade headlines pull markets in different directions, AI tools that can improve accuracy, access, and affordability in medicine are drawing close attention. The Transformative AI Healthcare Stocks screener looks for companies using AI to sharpen diagnostics, personalise treatment, streamline clinical...

If you are wondering whether Veradermics’ current share price lines up with its underlying value, this article breaks down what the numbers may indicate about the stock. Veradermics recently closed at US$107.85, with returns of 8.9% over 7 days, 90.2% over 30 days and 185.7% year to date. This puts the current price action firmly in focus for valuation-minded investors. Recent coverage around Veradermics has centered on its position within the Pharmaceuticals industry and how investors are...

If you are wondering whether Darling Ingredients at around US$62 is offering fair value or a potential discount right now, this article breaks down what the current price may be implying about the stock. The share price is at US$62.27, with a 3.1% decline over the last 7 days and a 2.0% decline over 30 days, set against a 65.4% gain year to date and an 84.0% return over the past year. This mix of recent pullbacks and longer term gains can change how you think about both upside and...

Omega Healthcare Investors (NYSE:OHI) is selling CommuniCare’s skilled nursing assets to lower tenant concentration risk. The move is part of a broader portfolio cleanup that also considers financial pressures at Maplewood and Genesis. The company aims to support dividend stability and overall portfolio health as operator stress continues across the sector. For investors watching NYSE:OHI at a share price of $46.13, this portfolio cleanup follows a very large 3-year return and a 94.0%...

Why Chime Financial stock is back in focus Chime Financial (CHYM) just posted its first GAAP profitable quarter since listing, along with 25% year over year revenue growth, a new Chime Prime membership tier, and a completed US$200 million share repurchase program. See our latest analysis for Chime Financial. Despite reporting its first GAAP profitable quarter and approving US$200 million of buybacks, Chime's 1 day share price return of a 12.5% decline and year to date share price return of a...

In April 2026, Everspin Technologies announced a US$40,000,000, 30‑month subcontract with Amentum Services under a U.S. Navy microelectronics RDT&E program, alongside first‑quarter 2026 results showing higher revenue and a smaller net loss than a year earlier. The deal ties Everspin’s Toggle MRAM process technology directly into U.S. defense supply chains, reinforcing its role as an on‑shore memory partner for critical systems. Next, we’ll examine how this US$40,000,000 defense-focused...

Wondering if ASML Holding at around US$1,516.60 is priced for perfection or still offers value? This article breaks down what the current share price really implies for you. The stock has returned 5.4% over the last week, 16.1% over the last month, 30.3% year to date and 115.6% over the past year, which naturally raises questions about where value and risk now sit. Recent coverage around ASML has emphasized its central role in semiconductor equipment and its importance to chip manufacturing...

Wondering whether Citizens Financial Group stock still offers value after its strong run, or if most of the easy gains are already behind it? This article walks through the key signals you can use to make that call. The stock last closed at US$64.22, with returns of 4.3% over 30 days, 8.1% year to date and 70.0% over 1 year, which can change how the market views both its growth potential and its risk profile. Recent coverage has focused on Citizens Financial Group's positioning as a major US...

Pomerantz LLP has opened an investigation into CarMax (NYSE:KMX) for potential securities fraud or other unlawful business practices. The inquiry follows CarMax's April 14, 2026 decision to lower used car prices and accept higher credit risk in response to an auto affordability crisis. The combination of a pricing shift and looser credit standards raises questions about risk management, disclosure, and long term business impacts. CarMax runs one of the largest used car retail operations in...

If you are wondering whether BioMarin Pharmaceutical's current share price reflects its true value, a useful starting point is understanding how the market has treated the stock recently. BioMarin's share price closed at US$54.12, with returns of 0.4% over 7 days, a 3.7% decline over 30 days, a 9.0% decline year to date, and a 9.5% decline over the last year, alongside longer term 43.3% and 28.3% declines over 3 and 5 years. These returns suggest many investors are likely reassessing whether...

This article examines whether Coty, trading at around US$2.50, may represent a bargain or a value trap by exploring what the current price could be implying about the stock. Coty's share price has moved by 1.6% over the last week and 18.5% over the last month. However, the stock is still showing a year to date return of a 19.6% decline and a 1 year return of a 48.1% decline. Recent news around Coty has focused on its positioning as a global beauty company, including ongoing brand activity...

If you are wondering whether Teledyne Technologies at around US$630 per share offers fair value or is pricing in too much optimism, the valuation picture is not as straightforward as the headline price suggests. The stock has seen a 2.3% decline over the last 7 days and a 0.7% decline over the last 30 days, while still sitting on returns of 21.6% year to date and 30.9% over the past year. Recent attention on Teledyne often centers on its position in high tech sensing, imaging and defense...

Palladyne AI Corp. recently reported past first-quarter 2026 results with revenue rising to US$3.54 million from US$1.71 million a year earlier, while swinging to a net loss of US$12.61 million and reaffirming full-year 2026 revenue guidance of US$24 million to US$27 million. The company also disclosed a roughly US$17 million backlog and new defense and space contracts, underlining growing demand for its embodied AI and autonomous systems offerings. Next, we’ll examine how reaffirmed...

What the latest guidance shift means for American Healthcare REIT (AHR) American Healthcare REIT (AHR) cut its 2026 net income guidance while highlighting a ninth straight quarter of double-digit same-store NOI growth and higher NFFO expectations, providing a mixed but detailed update on its outlook. See our latest analysis for American Healthcare REIT. Recent guidance cuts on 2026 net income sit alongside raised same store NOI and NFFO outlook, and the stock’s 1 month share price return of...

Century Aluminum (CENX) put up steady top line numbers in FY 2025, with fourth quarter revenue of US$633.7 million and basic EPS of US$0.02, capping a trailing twelve month run of US$2.5 billion in revenue and EPS of US$0.42. Over the past reported periods, quarterly revenue has moved in a tight band between US$628.1 million and US$633.9 million, while basic EPS has ranged from a quarterly loss of US$0.05 to a high of US$0.30. This sets up a story where investors are weighing solid revenue...

Why CSG Systems International Is On Investors’ Radar Today CSG Systems International (CSGS) is drawing attention after a period of steady share price performance, leaving investors weighing how its current valuation lines up with recent returns and fundamentals. See our latest analysis for CSG Systems International. At a share price of $80.39, CSG Systems International has seen relatively steady short term share price returns. A 1 year total shareholder return of 25.55% and 5 year total...

If you are wondering whether BioCryst Pharmaceuticals, at a last close of US$8.90, still offers value, it helps to step back and look at the full valuation picture rather than just the recent share price. The stock is up 18.7% year to date, although it has seen a 2.8% decline over the last week and a 7.2% decline over the last month, and the 1 year return sits at a 10.3% decline. Recent news coverage has focused on BioCryst Pharmaceuticals' pipeline progress and its positioning within the...

Nextpower (NasdaqGS:NXT) has appointed Lindsey Wiedmann as its new Chief Legal and Compliance Officer. Wiedmann steps in following the retirement of Bruce Ledesma from the role. She previously held senior legal and compliance responsibilities at Maxeon Solar Technologies, bringing sector specific experience. For readers tracking NasdaqGS:NXT, this shift in leadership comes at a time when solar and broader clean energy businesses are closely watched for how they handle regulation, policy...

Event context and recent share performance Andersen Group (ANDG) recently drew investor interest after a session that left the stock at $35.98, with single day and past week returns of 2.27% and 1.70% respectively. Over the past month and past 3 months, Andersen Group has delivered returns of 25.58% and 67.97%, while year to date the stock shows a 47.58% total return. See our latest analysis for Andersen Group. For context, Andersen Group's recent 1 month share price return of 25.58% and 3...

StandardAero (SARO) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$0.24, supported by trailing 12 month revenue of US$6.1b and EPS of US$0.84 that sit against a very large reported earnings expansion over the past year. The company has seen quarterly revenue move from US$1.41b in Q4 2024 to US$1.60b in Q4 2025, while basic EPS shifted from a loss of US$0.04 to a profit of US$0.24 over the same period, with trailing net profit margins now framed against a...